- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Amyloid light-chain (AL) amyloidosis
- Meeting Date: November 2021
- Public Summary Document (PSD) November 2021 PBAC Meeting - (PDF 1995KB)
- Public Summary Document (PSD) November 2021 PBAC Meeting - (Word 773KB)
Daratumumab – November 2021
Daratumumab: Solution for subcutaneous injection 1,800 mg in 15 mL vial; Darzalex SC®
Last updated
18 March 2022